These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 12783216)
1. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Chakraborty NG; Stevens RL; Mehrotra S; Laska E; Taxel P; Sporn JR; Schauer P; Albertsen PC Cancer Immunol Immunother; 2003 Aug; 52(8):497-505. PubMed ID: 12783216 [TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539 [TBL] [Abstract][Full Text] [Related]
3. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer. Elkord E; Williams PE; Kynaston H; Rowbottom AW Int Immunol; 2005 Oct; 17(10):1315-25. PubMed ID: 16141246 [TBL] [Abstract][Full Text] [Related]
4. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors. Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193 [TBL] [Abstract][Full Text] [Related]
5. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals. Forsberg O; Carlsson B; Malmström PU; Ullenhag G; Tötterman TH; Essand M Prostate; 2009 Jan; 69(1):70-81. PubMed ID: 18814178 [TBL] [Abstract][Full Text] [Related]
6. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Xue BH; Zhang Y; Sosman JA; Peace DJ Prostate; 1997 Feb; 30(2):73-8. PubMed ID: 9051144 [TBL] [Abstract][Full Text] [Related]
7. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. Kouiavskaia DV; Berard CA; Datena E; Hussain A; Dawson N; Klyushnenkova EN; Alexander RB J Immunother; 2009; 32(6):655-66. PubMed ID: 19483644 [TBL] [Abstract][Full Text] [Related]
8. Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer. Perambakam S; Xue BH; Sosman JA; Peace DJ Cancer Immunol Immunother; 2002 Jul; 51(5):263-70. PubMed ID: 12070713 [TBL] [Abstract][Full Text] [Related]
9. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Perambakam S; Hallmeyer S; Reddy S; Mahmud N; Bressler L; DeChristopher P; Mahmud D; Nunez R; Sosman JA; Peace DJ Cancer Immunol Immunother; 2006 Sep; 55(9):1033-42. PubMed ID: 16283303 [TBL] [Abstract][Full Text] [Related]
10. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. Correale P; Walmsley K; Zaremba S; Zhu M; Schlom J; Tsang KY J Immunol; 1998 Sep; 161(6):3186-94. PubMed ID: 9743387 [TBL] [Abstract][Full Text] [Related]
11. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592 [TBL] [Abstract][Full Text] [Related]
12. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols. Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173 [TBL] [Abstract][Full Text] [Related]
13. DCs pulsed with novel HLA-A2-restricted CTL epitopes against hepatitis C virus induced a broadly reactive anti-HCV-specific T lymphocyte response. Guo Z; Zhang H; Rao H; Jiang D; Cong X; Feng B; Wang J; Wei L; Chen H PLoS One; 2012; 7(6):e38390. PubMed ID: 22701633 [TBL] [Abstract][Full Text] [Related]
14. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Olson BM; Frye TP; Johnson LE; Fong L; Knutson KL; Disis ML; McNeel DG Cancer Immunol Immunother; 2010 Jun; 59(6):943-53. PubMed ID: 20140431 [TBL] [Abstract][Full Text] [Related]
15. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. Correale P; Walmsley K; Nieroda C; Zaremba S; Zhu M; Schlom J; Tsang KY J Natl Cancer Inst; 1997 Feb; 89(4):293-300. PubMed ID: 9048833 [TBL] [Abstract][Full Text] [Related]
16. CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Olson BM; McNeel DG Cancer Immunol Immunother; 2011 Jun; 60(6):781-92. PubMed ID: 21350948 [TBL] [Abstract][Full Text] [Related]
17. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604 [TBL] [Abstract][Full Text] [Related]
18. Generation of functional CD8+ T cells by human dendritic cells expressing glypican-3 epitopes. O'Beirne J; Farzaneh F; Harrison PM J Exp Clin Cancer Res; 2010 May; 29(1):48. PubMed ID: 20465843 [TBL] [Abstract][Full Text] [Related]
19. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
20. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]